Trials / Completed
CompletedNCT01163227
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo (single and multiple doses) | |
| DRUG | AQW051 2 mg (single and multiple doses) | |
| DRUG | AQW051 15mg (single and multiple doses) | |
| DRUG | AQW051 100mg (single dose), and 50mg (multiple doses) |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-07-15
- Last updated
- 2020-12-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01163227. Inclusion in this directory is not an endorsement.